All In Biotech

Drug Trial Radar · NCT05682443

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

148

Actual

Start

Dec 11, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2027

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
Collaborators
Prostate Cancer Clinical Trials Consortium
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • ONC-392 lowDrug

    ONC-392 will be given as IV infusion, Q4W for up to 13 doses.

  • ONC-392 highDrug

    ONC-392 will be given as IV infusion, Q6W for up to 9 doses.

  • lutetium Lu 177 vipivotide tetraxetanDrug

    lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT (Dose escalation Phase 1)Time frame: 40 months
  2. PSA50 (Dose Expansion Phase 2)Time frame: 40 months
  3. rPFS (Dose Expansion Phase 2)Time frame: 40 months
  4. TEAEs and irAEs (Dose Expansion Phase 2)Time frame: 40 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Rocky Mountain Cancer Centers USOR

    Aurora, Colorado

  • Moffitt Cancer Cancer

    Tampa, Florida

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Chesapeake Urology Research Associates

    Towson, Maryland

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • XCancer/GU Research Network

    Omaha, Nebraska

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • New Mexico Oncology Hematology Consultants

    Albuquerque, New Mexico

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • NYU Langone Health, Laura & Isaac Perlmutter Cancer Center

    New York, New York

  • Columbia University Irving Cancer Center

    New York, New York

  • UNC North Carolina Comprehensive Cancer Care Center

    Chapel Hill, North Carolina

  • Duke Cancer Center

    Durham, North Carolina

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • UT Southwestern Medical Center

    Dallas, Texas

  • Virginia Cancer Specialists USOR

    Fairfax, Virginia

  • Virginia Oncology Associates USOR

    Norfolk, Virginia

  • Oncology and Hematology Associates Of Southwest Virginia USOR

    Norton, Virginia

  • UW Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.